Analysis of antibody repertoires of COVID-19 patients revealed a burst of IgG and IgA clones with low SHM in T2 and T3, indicating SARS-CoV-2-specific IgG and IgA clones derived from naive B cells in these time points. This evidence concerns the gene CD79A and COVID-19.